Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Buckner

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade GliomaErica H Bell, Peixin Zhang, Edward G Shaw, et al.
The American Journal of Managed Care|June 15, 2012
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancersKeith C Bible, Robert C Smallridge, John C Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
SSBP2 variants are associated with survival in glioblastoma patientsYuanyuan Xiao, Paul A Decker, Terri Rice, et al.
Journal of Oncology Practice|September 4, 2012
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancersKeith C Bible, Robert C Smallridge, John C Morris, et al.
Journal of Geriatric Oncology|June 16, 2019
Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology, Araba Adjei, Jan C Buckner, et al.
Journal of the National Cancer Institute|June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trialsJeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
Nature Genetics|August 28, 2012
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutationRobert B Jenkins, Yuanyuan Xiao, Hugues Sicotte, et al.
The New England Journal of Medicine|June 11, 2015
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in TumorsJeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade GliomaErica H Bell, Peixin Zhang, Edward G Shaw, et al.
The American Journal of Managed Care|June 15, 2012
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancersKeith C Bible, Robert C Smallridge, John C Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
SSBP2 variants are associated with survival in glioblastoma patientsYuanyuan Xiao, Paul A Decker, Terri Rice, et al.
Journal of Oncology Practice|September 4, 2012
Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancersKeith C Bible, Robert C Smallridge, John C Morris, et al.
Journal of Geriatric Oncology|June 16, 2019
Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology, Araba Adjei, Jan C Buckner, et al.
Journal of the National Cancer Institute|June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trialsJeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
Nature Genetics|August 28, 2012
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutationRobert B Jenkins, Yuanyuan Xiao, Hugues Sicotte, et al.
The New England Journal of Medicine|June 11, 2015
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in TumorsJeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, et al.
Pageof 14